{"article_title": "Biogen\u2019s Tough Treatment from Wall Street", "article_keywords": ["biogens", "tough", "wall", "respectively", "results", "sales", "reported", "street", "period", "treatment", "served", "slumped", "reminder", "markets", "stock"], "article_url": "http://www.wsj.com/articles/biogens-tough-treatment-from-wall-street-1429903044", "article_text": "Biogen\u2019s first-quarter results served as the latest reminder that markets just aren\u2019t that into history.\n\nBiogen reported on Friday that sales and earnings in the first period jumped by 20% and 72%, year over year, respectively. The stock slumped 6%...", "article_metadata": {"article.template": "snippet", "article.created": "2015-04-24T19:17:00.000Z", "article.section": "Markets", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "High expectations for Biogen\u2019s multiple-sclerosis drug are a significant obstacle for the stock.", "title": "Biogen\u2019s Tough Treatment from Wall Street", "image": {"src": "https://si.wsj.net/public/resources/images/BN-IB107_0424bi_G_20150423123834.jpg", "alt": "Biogen\u2019s Tough Treatment from Wall Street", "identifier": "https://si.wsj.net/public/resources/images/BN-IB107_0424bi_D_20150423123834.jpg"}, "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11156702552649734117904580600662695449690&headline=Biogen%u2019s%20Tough%20Treatment%20from%20Wall%20Street&weburl=http://www.wsj.com/articles/SB11156702552649734117904580600662695449690"}}, "page.site.product": "WSJ", "keywords": "biogen,drugs,earnings,first quarter,kyle bass,multiple sclerosis,tecfidera,Biogen,BIIB,biotechnology,political,general news,health,sciences,technologies,pharmaceuticals,health care,life sciences", "news_keywords": "biogen,drugs,earnings,first quarter,kyle bass,multiple sclerosis,tecfidera,Biogen,BIIB,biotechnology", "article.headline": "Biogen\u2019s Tough Treatment from Wall Street", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-IB107_0424bi_E_20150423123834.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-IB107_0424bi_D_20150423123834.jpg"}}, "description": "High expectations for Biogen\u2019s multiple-sclerosis drug are a significant obstacle for the stock.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11156702552649734117904580600662695449690&headline=Biogen%u2019s%20Tough%20Treatment%20from%20Wall%20Street&weburl=http://www.wsj.com/articles/SB11156702552649734117904580600662695449690", "user.type": "nonsubscriber", "article.page": "Heard on the Street", "page.content.format": "responsive", "article.summary": "High expectations for Biogen\u2019s multiple-sclerosis drug are a significant obstacle for the stock.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-04-24T19:17:00.000Z", "dj.asn": "i-e96b", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"internal_link_count": 1, "publisher": "https://www.facebook.com/wsj", "image_count": 1, "word_count": 179, "external_link_count": 1}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "High expectations for Biogen\u2019s multiple-sclerosis drug are a significant obstacle for the stock.", "title": "Biogen\u2019s Tough Treatment from Wall Street", "url": "http://www.wsj.com/articles/biogens-tough-treatment-from-wall-street-1429903044", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-IB107_0424bi_G_20150423123834.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Charley Grant", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Biogen\u2019s Tough Treatment from Wall Street", "article.type": "Heard on the Street", "article.id": "SB11156702552649734117904580600662695449690", "user.exp": "default", "article.updated": "2015-04-24T19:17:00.000Z"}, "_id": "\"57477af46914bd0286fe10d5\"", "article_summary": "Biogen\u2019s first-quarter results served as the latest reminder that markets just aren\u2019t that into history.\nThe stock slumped 6%...\nBiogen reported on Friday that sales and earnings in the first period jumped by 20% and 72%, year over year, respectively."}